Difference between revisions of "Pamidronate (Aredia)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "Also known as pamidronate disodium omega, Pamisol, PMS-pamidronate, or Rhoxal-pamidronate. ==General information== Class/mechanism: Bisphosphonate, inhibits osteoclast activity ...")
 
m (Text replace - "or the prescribing information<ref name="insert"></ref>." to "or the prescribing information.<ref name="insert"></ref>")
Line 6: Line 6:
 
<br>Extravasation: no information
 
<br>Extravasation: no information
  
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information<ref name="insert"></ref>.
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
  
 
==Patient drug information==
 
==Patient drug information==

Revision as of 06:41, 13 May 2012

Also known as pamidronate disodium omega, Pamisol, PMS-pamidronate, or Rhoxal-pamidronate.

General information

Class/mechanism: Bisphosphonate, inhibits osteoclast activity and bone resorption. Exact mechanism not understood, but is believed to also involve blocking dissolution of bone calcium phosphate (hydroxyapatite) crystals.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

References